The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development.

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

A new National Academies report recommends ways for the U.S. to reap the benefits of artificial intelligence in biotechnology ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

In essence, the future of AI is inextricably linked to advancements in data management, making it an indispensable enabler of ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...

The collaboration will leverage Nosis’ Connexa™ platform, an advanced AI-powered drug design and delivery system, to enable therapeutic access to extrahepatic cell types across multiple vital ...

Insilico and rivals like Atomwise Inc. and BenevolentAI aim to use AI to improve drug discovery, historically a time-consuming and costly process. It’s one of the fields AI optimists have been ...

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...